Pharmacist intervention does not prevent medication errors

Pharmacist intervention does not prevent medication errors
A pharmacist-delivered intervention does not significantly improve the rate of clinically important medication errors following discharge among hospitalized heart patients, according to a study published in the July 3 issue of the Annals of Internal Medicine.

(HealthDay) -- A pharmacist-delivered intervention does not significantly improve the rate of clinically important medication errors following discharge among hospitalized heart patients, according to a study published in the July 3 issue of the Annals of Internal Medicine.

Sunil Kripalani, M.D., from Vanderbilt University in Nashville, Tenn., and colleagues assessed the effect of a tailored pharmacist-delivered intervention on the occurrence of clinically important medication errors for 851 patients discharged following hospitalization with or acute decompensated . Participants were randomly allocated to either usual care or an intervention of pharmacist-assisted medication reconciliation, inpatient pharmacist counseling, low-literacy adherence aids, and individualized telephone follow-up after discharge.

The researchers found that 50.8 percent of patients had one or more clinically important medication errors, of which 22.9 percent were serious and 1.8 percent were life-threatening. Overall, 30.3 percent of patients had adverse drug events (ADEs), and potential ADEs occurred in 29.7 percent. There was no significant change in the number of clinically important or ADEs per-patient for those in the intervention group (unadjusted incidence rate ratio [IRR], 0.92 [95 percent confidence interval (CI), 0.77 to 1.10] and 1.09 [95 percent CI, 0.86 to 1.39], respectively). There tended to be fewer potential ADEs in those receiving the intervention (unadjusted IRR, 0.80; CI, 0.61 to 1.04).

"A health-literacy-sensitive pharmacist intervention that included post-discharge telephone follow-up did not improve overall," the authors write. "Reducing ADEs and potential ADEs in the post-discharge period is becoming more critical as hospitals have increasing financial penalties tied to rehospitalization rates."

More information: Full Text (subscription or payment may be required)

add to favorites email to friend print save as pdf

Related Stories

Thousands of patients prescribed high-risk drugs

Jun 22, 2011

Thousands of patients in Scotland who are particularly vulnerable to adverse drug events (ADEs) were prescribed high-risk medications by their GPs which could potentially cause them harm, according to research published in ...

Recommended for you

Xtoro approved for swimmer's ear

Dec 18, 2014

(HealthDay)—Xtoro (finafloxacin otic suspension) eardrops have been approved by the U.S. Food and Drug Administration to treat swimmer's ear, clinically known as acute otitis externa.

Drug interaction identified for ondansetron, tramadol

Dec 18, 2014

(HealthDay)—In the early postoperative period, ondansetron is associated with increased requirements for tramadol consumption, according to a review and meta-analysis published online Dec. 10 in Anaesthesia.

New system targets germs in donated blood plasma

Dec 17, 2014

(HealthDay)—A new system designed to eliminate germs in donated blood plasma and reduce the risk of transmitting a plasma-borne infection has been approved by the U.S. Food and Drug Administration.

Judge halts Alzheimer's drug swap until July

Dec 16, 2014

A federal judge has ordered an Irish drug manufacturer to halt its plans to discontinue its widely used Alzheimer's medication, allegedly in an effort to drive patients to a newer patented drug.

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.